Your browser doesn't support javascript.
loading
Safety and Relative Dose Intensity of Dose-dense Doxorubicin and Cyclophosphamide Followed by Dose-dense Paclitaxel.
Nishimura, Meiko; Onoe, Takuma; Sakai, Hideki; Arase, Minori; Watanabe, Sayuri; Soyama, Misao; Hashimoto, Kazuki; Miki, Mayuko; Tane, Kaori; Hirokaga, Koichi; Takao, Shintaro; Matsumoto, Koji.
Afiliación
  • Nishimura M; Department of Medical Oncology, Hyogo Cancer Center, Akashi, Japan.
  • Onoe T; Department of Medical Oncology, Hyogo Cancer Center, Akashi, Japan.
  • Sakai H; Department of Medical Oncology, Hyogo Cancer Center, Akashi, Japan.
  • Arase M; Department of Pharmacy, Hyogo Cancer Center, Akashi, Japan.
  • Watanabe S; Department of Pharmacy, Hyogo Cancer Center, Akashi, Japan.
  • Soyama M; Department of Breast Surgery, Hyogo Cancer Center, Akashi, Japan.
  • Hashimoto K; Department of Breast Surgery, Hyogo Cancer Center, Akashi, Japan.
  • Miki M; Department of Breast Surgery, Hyogo Cancer Center, Akashi, Japan.
  • Tane K; Department of Breast Surgery, Hyogo Cancer Center, Akashi, Japan.
  • Hirokaga K; Department of Breast Surgery, Hyogo Cancer Center, Akashi, Japan.
  • Takao S; Department of Breast Surgery, Hyogo Cancer Center, Akashi, Japan.
  • Matsumoto K; Department of Medical Oncology, Hyogo Cancer Center, Akashi, Japan kojmatsu2@hyogo-cc.jp.
Anticancer Res ; 39(8): 4379-4383, 2019 Aug.
Article en En | MEDLINE | ID: mdl-31366533
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Doxorrubicina / Paclitaxel / Ciclofosfamida Tipo de estudio: Risk_factors_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Anticancer Res Año: 2019 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Grecia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Doxorrubicina / Paclitaxel / Ciclofosfamida Tipo de estudio: Risk_factors_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Anticancer Res Año: 2019 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Grecia